Prevalence, trends and outcomes of long-term inhaled antibiotic treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection – A European cystic fibrosis patient registry data analysis

Highlights

• We searched the ECFS-PR for inhaled antibiotic use in pwCF without PA infection.
• 30% of pwCF not chronically PA infected were treated with inhaled antibiotics.
• The major determinant of inhaled antibiotic use is past chronic infection with PA.
• Over follow up, no benefit has been seen for treatment with inhaled antibiotics.
• Randomized trials of inhaled antibiotics in pwCF without PA infection are needed.